Ble for the design and implementation of this study analyzed all of the study, creation and editing of the manuscript and its final contents. The study is to registered identifier NCT00997503. Summary of the study and the TAXUS Libert status post licensure study are long-term data on the use of the Wnt Pathway TAXUS Libert paclitaxeleluting stenting offer with platelet aggregation inhibitors with prasugrel in patients without concomitant in clinical practice selected Hlt routine that weight Arranty security and effectiveness of data in complex coronary L sions and clinical parameters that are represented in randomized TAXUS Libert. Approximately 4,200 patients will be prescribed prasugrel and aspirin for 12 months after stent implantation, so this study is the first study to evaluate use of prasugrel in unselected patients receiving the TAXUS Liberté stent. The study is a point of the first 12 months sp T cardiac death or MI were treated, compared with a historical group of patients with the Taxus Express stent. In addition, as a secondary key Rer endpoint is powered the study to the j Hrlichen rates of ST additional 5 years in patients treated with the Taxus Liberté stent judge a performance goal for the TAXUS Express Stent compared. Other endpoints Todesf ll From any cause, stroke, revascularization, and bleeding in both on and off-label stent patients. In addition, for the first time that a maintenance dose of 5 mg of prasugrel in patients 75 years or kg B60, previously served as an h Higher risk of bleeding after the use of prasugrel 10 mg identified are evaluated.
After 12 months of open-label, prasugrel, is randomly assigned eligible patients received either aspirin or placebo plus an additional 18 months of prasugrel plus aspirin, contributed data to the study randomized more DAPT developed to determine the optimal duration of study of dual antiplatelet therapy after PCI with DES for the placement for the treatment of coronary TAXUS Libert lesions.9 The post-approval study, therefore, will provide information on long-term use of the benefits of the TAXUS paclitaxel Libert stent-graft therapy with platelet aggregation inhibitors with prasugrel in a wide range of stent receptn Ngern additionally tzlich to provide data on prasugrel dose and duration of optimal subsets of patients at high risk. The first patient in the TAXUS Libert after approval in December 2009 were registered from September 2011 were 4,000 patients enrolled in the United States. The completion of the registration is scheduled for December 2011, and prime Re endpoint data should initially Highest mid-2013. Acknowledgments We thank the following individuals at Boston Scientific: Svetozar Grgurevich, PhD, and Kristin L. Hood, Ph.D. forassistance, in the creation and MK-8669 editing of the manuscript, Ruth M. Starzyk, PhD, for critically reading the manuscript, Peter S. Lam, Ph.D., for his contributions GE to study the statistical analysis plan, and Kevin Najarian, Nihen Barbara, and Donald S. Baim, MD, for valuable information about the study design. We also thank Eileen Brown, Ph.D., for his contributions GE to study the statistical analysis plan. Patients infected with HIV with increased Hten risk for developing malignancies. A number of factors Including, Lich deregulation of the immune system, chronic stimulation and direct viral.